Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F.
Ramos Perez JM, et al. Among authors: rivera d.
Leuk Lymphoma. 2022 Mar;63(3):672-675. doi: 10.1080/10428194.2021.1992757. Epub 2021 Oct 20.
Leuk Lymphoma. 2022.
PMID: 34668451